UMPS deficiency case, the importance of multi-omics diagnostics


April 2021, X Omics festival Lonneke de Boer, metabolic pediatrician

Radboudumc

UMPS: Uridine Monophosphate Synthase Deficency

Radboudumc

Disorder in the pyrimidine metabolism




case

- 3 year old boy
- History
 - 2nd child of non consanguineous parents, one miscarriage
 - Prematurely born 30 weeks
 - Congenital urethral valves, surgically treated
 - Congenital normocytic transfusion dependent anemia, also a mild leucocytopenia with neutropenia. Blood transfusions every 5-7 weeks
 - 3 months: nefrocalcinosis/lithiasis and dilated pyelum (left)

- 2 years acute kidney failure due to obstruction by kidney stones
- Motor and speech development adequate
- Height -1.2 SD and weight for height -0.8 SD
- Diagnostic workup congenital anemia, ringsideroblasts without hemolysis
- Karyotyping normal 46 XY
- Exome sequencing anemia panels, trio WES

- Result trio WES: heterozygous mutation in SEC23B, associated with dyserythropoietic anemia type II (CSAII) in case of bi-allelic mutations
- After 2 years of diagnostics it was decided to do metabolic screening
- Metabolic screening
- UOA and purine/pyrimidine analysis: very high orotic acid: 3404 umol/mmol kreat (ref 0-4) without indication in the serum amino acids for a urea cycle disorder
- Diagnosis: UMPS deficiency/ hereditairy orotic aciduria



UMPS deficiency/ hereditairy orotic aciduria

- Kidney stones due to orotic acid stones
- Anemia due to decreased production of UMP, leading to impairment cell division/erytropoiesis
- Impairment growth/development

- Enzyme analysis erytrocytes not possible due to frequent blood transfusions, fibroblasts?
- Re analysis trio WES:
 - UMPS: 866A>G (Asp289Gly) and 1064A>C (Gln355Pro), compound heterozygous, first classified as class 2/3. Predicted non pathogenic by mutation predictive software, although not mentioned in sequence variant databases. Not mentioned in literature.

- Kidney stone analysis orotic acid stone
- Enzyme analysis: UMPS activity in erytrocytes: deficient

Treatment

- 1969 Becroft er al: Hereditairy orotic aciduria: long term therapy with uridine and a trial of uracil
- 2014 Shanti Balasubramaniam et al JIMD, Inborn errors of pyridmidine metabolism, clinical update and therapy
- Trial uridine tri acetate (Xuriden), registered in US, expensive (800.000 euro's per year?), not registered in the Netherlands
- 15 cases reported, in the Netherlands in the meantime 2 patients
- Radboud pharmacy: permission import IGJ, but route difficult and second step financial compensation insurance company

- Uridine: 150-300 mg/kg
- Xuriden 60 mg/kg, max 120 mg/kg

- 89 euro for 150 gram
- Food supplement good for concentration



- Started on 60 mg/kg in january 2020
- From blood transfusions every 5-7 weeks, no blood transfusions needed now for one year
- Reticulocytes and leucocytes increased
- Much more energy, eating is better, growth improved
- But orotic acid levels still high, effect on kidney has to be seen
- Higher dose uridine

Summary

- Metabolic screening really here added quality of life to this patient
 - Combination of Metabolic diagnostics and data of whole exome sequencing has lead to the diagnosis
- Impressive effect of uridine therapy
- Issues
- GMP manufactered product in the Netherlands
- Financial compensation by insurance company

Thank you for your attention

Translational Metabolic Laboratory

Karlien Coene Leo Kluijtmans Marleen Huigen Bert van den Heuvel



Jurgen Bierau

Human Genetics Nijmegen

Amalia Childrens Hospital

Paul Brons, haematologist Pieter van den Nieuwenhuizen, Childrens tv/film

